",n.parentNode.insertBefore(a,n)};if(!!document.cookie.match(/cookieConsent=true/))window.gaf(); ',{'forceSSL':true});

news

Kalos Therapeutics Announces 55 million Euro investment Commitment from GEM as Company Seeks to go Public in Coming Months

     (2 March 2021)  Kalos prepares to list in Frankfurt via reverse merger or traditional IPO.

ValiRx PLC Agreement with Kalos Therapeutics:

    (10 November 2020) ValiRx (AIM: VAL) a clinical stage drug development company, announces today that it has entered into an agreement with Kalos Therapeutics (Kalos), a US-based private biotechnology company, to evaluate its peptide KTH222 as a drug candidate for treating patients with ovarian cancer.

Kalos Therapeutics Announces Early Positive Data Against SARS-CoV-2 For COVID-19 Program:

    (August 21, 2020) Kalos Therapeutics today announced positive preclinical efficacy results from a series of Kalos peptides for the treatment of COVID-19.

Kalos therapeutics announces important progress in therapeutic peptide for cancer program:

    (May 30, 2020 ) Kalos therapeutics is developing a novel, small peptide with activity against human pancreatic cancer

© 2020 Kalos Therapeutics. All Rights Reserved.

This website makes use of cookies. Please see our privacy policy for details.

OK